(CercleFinance.com) – Amoéba shares fell 3% on Monday following the announcement of the departure of its general director and the delay in the implementation of its industrial project.
The biotech, specializing in the treatment of microbiological risks, announced on Friday that it had decided to separate the mandates of chairman of the board of directors and general director, which will result in the termination of the functions of Fabrice Plasson.
The role of general manager has been entrusted to Jean-François Doucet, previously deputy general manager, but it is expected that Fabrice Plasson will continue his commitment to the company he founded 13 years ago.
He will be responsible in particular for supporting the development of Amoéba as a founding director and by being involved in the strategic vision of the company within the board.
These decisions result, according to Amoéba, from the evolution of its strategic partnership with its reference shareholder, the Swiss Nice & Green, which currently holds 29.4% of the capital and which is thus committed to continuing the financing of Amoéba’s current activities until the entry of new investors.
Pending obtaining new financing, Amoéba says it has taken the decision to postpone the construction of its industrial project known as ‘Usibiam’ in Cavaillon, a postponement which in no way affects the continuation of current commercial procedures.